Victory Capital Management Inc. Decreases Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Victory Capital Management Inc. reduced its stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 1.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,160 shares of the company’s stock after selling 930 shares during the period. Victory Capital Management Inc. owned about 0.09% of Tyra Biosciences worth $754,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. RA Capital Management L.P. increased its stake in shares of Tyra Biosciences by 43.9% during the first quarter. RA Capital Management L.P. now owns 10,416,609 shares of the company’s stock valued at $170,832,000 after buying an additional 3,180,155 shares during the period. BVF Inc. IL increased its stake in shares of Tyra Biosciences by 70.1% during the first quarter. BVF Inc. IL now owns 4,661,194 shares of the company’s stock valued at $76,444,000 after buying an additional 1,921,599 shares during the period. Vanguard Group Inc. increased its stake in shares of Tyra Biosciences by 18.6% during the first quarter. Vanguard Group Inc. now owns 899,800 shares of the company’s stock valued at $14,757,000 after buying an additional 140,833 shares during the period. Kynam Capital Management LP increased its stake in shares of Tyra Biosciences by 51.4% during the first quarter. Kynam Capital Management LP now owns 515,190 shares of the company’s stock valued at $8,449,000 after buying an additional 175,000 shares during the period. Finally, Wellington Management Group LLP increased its stake in shares of Tyra Biosciences by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 102,436 shares of the company’s stock valued at $1,419,000 after buying an additional 8,324 shares during the period. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Stock Performance

Shares of Tyra Biosciences stock opened at $24.36 on Friday. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -14.50 and a beta of 1.01. The stock has a 50 day moving average price of $21.29 and a 200-day moving average price of $18.72. Tyra Biosciences, Inc. has a one year low of $10.38 and a one year high of $25.14.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Sell-side analysts predict that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TYRA has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $23.00 price target on shares of Tyra Biosciences in a research report on Wednesday, July 3rd. Piper Sandler assumed coverage on Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price on the stock. Wedbush reissued an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a report on Thursday, August 8th. Finally, Oppenheimer upped their price target on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $26.40.

Insider Buying and Selling

In related news, CEO Todd Harris sold 5,698 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $24.31, for a total transaction of $138,518.38. Following the completion of the sale, the chief executive officer now directly owns 1,496,729 shares of the company’s stock, valued at approximately $36,385,481.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.40% of the stock is owned by corporate insiders.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.